hepatocellular carcinoma
Conditions
Interventions
Case series:no intervention
Sponsors
Ningbo Second Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged >=18 years old; 2. ECOG 0-2; 3. Primary hepatocellular carcinoma that meets the clinical diagnostic criteria of the "Specifications for the Diagnosis and Treatment of Primary Liver Cancer" (2019 Edition) or confirmed by histopathological/cytological examination; 4. According to the RECIST 1.1 standard, at least one measurable target lesion exists; 5. Have not received systemic treatment for hepatocellular carcinoma in the past; 6. Physicians believe that they may benefit from carrelizumab treatment and voluntarily accept treatment; 7. Sign informed consent and agree to collect patients' clinical efficacy and information.
Exclusion criteria
Exclusion criteria: 1. Local treatment have received local treatment within 1 month before the first administration of Carrelizumab; 2. Women during pregnancy or lactation; 3. Patients who have hypersensitivity to the active ingredient of carrelizumab or any of the excipients listed in [ingredients]; 4. Incomplete important imaging examinations and incomplete records of adverse reactions; 5. Other situations that are not suitable for inclusion in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| objective response rate; | — |
Countries
China
Contacts
Public ContactZhu Dedong
Ningbo Second Hospital
Outcome results
None listed